NCT00301067View on ClinicalTrials.gov

Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 30, 2005

Primary Completion Date

April 5, 2012

Study Completion Date

July 9, 2012

Conditions
Metastatic Melanoma
Interventions
DIETARY_SUPPLEMENT

Calcitriol

The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle

DRUG

Temozolomide

The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle

Trial Locations (1)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00301067 - Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter